Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder

J Urol. 2011 Sep;186(3):960-4. doi: 10.1016/j.juro.2011.04.071. Epub 2011 Jul 24.

Abstract

Purpose: In this 6-month followup study we investigated the effect of intradetrusor injection of 100 U botulinum toxin type A in patients with Parkinson's disease and refractory detrusor overactivity.

Materials and methods: Eight patients with Parkinson's disease and detrusor overactivity refractory to anticholinergics were injected with 100 U botulinum toxin type A. Daytime and nighttime urinary frequency, and urinary incontinence episodes were recorded. Patients also completed a standardized quality of life questionnaire on incontinence and a visual analog scale on the impact of bladder problems on daily life activities, and underwent urodynamic assessment, including pressure flow studies. Clinical and urodynamic assessment was performed before, and 1, 3 and 6 months after injection.

Results: In all patients 100 U botulinum toxin type A induced decreased daytime and nighttime urinary frequency, a decreased number of urinary incontinence episodes, increased quality of life scores and, as shown by increased maximum cystometric capacity, improved urodynamic findings. In 2 patients with Parkinson's disease post-void residual urine volume developed.

Conclusions: Intradetrusor injection of 100 U botulinum toxin type A induced clinical and urodynamic improvement in overactive bladder symptoms that lasted at least 6 months in patients with Parkinson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Botulinum Toxins, Type A / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Neuromuscular Agents / therapeutic use*
  • Parkinson Disease / complications*
  • Time Factors
  • Urinary Bladder, Overactive / drug therapy*
  • Urinary Bladder, Overactive / etiology*

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A